Following the Phuket–Delhi serious incident on Air India flight AI2379, the government has directed the airline to strengthen operational oversight and instructed the Directorate General of Civil Aviation to revisit its drug-testing regime with urgency. The expected changes include raising the proportion of aviation personnel subject to testing, sharpening penalties for confirmed use of prohibited substances, and creating clearer pathways for further examination when a positive result may be linked to prescribed medication. Air India has already moved ahead of the regulator by ordering mandatory screening of all group pilots for substances and medications not permitted under current rules.
The policy question is not whether impairment has any place in the cockpit. It does not. The harder design problem is how to build a system that deters illicit use while remaining fair to pilots and crew who take legitimate prescribed medicine, disclose treatment, or seek mental-health support. Existing DGCA procedures already require confirmatory testing after an initial non-negative screen and consultation with a medical review officer to distinguish therapeutic sources from abuse. The new direction appears to expand coverage, tighten consequences for confirmed prohibited use, and formalise additional testing or review steps when medication is cited.
That balance matters. A regime that treats every positive result as automatic career-ending misconduct risks driving legitimate medical issues underground. Pilots who need short-term sleep medication, anxiety treatment or other prescribed drugs may delay disclosure or avoid care if they believe any laboratory finding will be treated as evidence of impairment rather than a medical fact requiring explanation. At the same time, a system that is too slow or too permissive fails passengers who rightly expect that no one operating an aircraft is under the influence of substances that degrade performance.
Effective design therefore requires clear lists of prohibited substances, robust confirmatory testing, independent medical review, protection for those who self-report prescribed treatment in advance, and proportionate sanctions that distinguish isolated medical findings from deliberate non-compliance. It also requires enough testing volume and randomness to create genuine deterrence without becoming purely punitive theatre. Mental-health support pathways that encourage early disclosure rather than concealment form part of the same safety architecture.
India’s aviation system is expanding rapidly. The number of pilots, cabin crew and other safety-sensitive personnel is rising with it. A drug-testing framework written for a smaller industry will not automatically scale. The government and DGCA now have the opportunity to rewrite the rules so that fitness to fly is assessed with both scientific rigour and medical fairness. The measure of success will not be the number of positive tests recorded, but whether the system prevents impairment while still allowing aviation professionals to seek legitimate care without fear that honesty itself becomes a career risk.